Four-pronged attack on PDAC

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2024-10-08 DOI:10.1038/s41568-024-00765-9

Gabrielle Brewer

引用次数: 0

Abstract

Chibaya, DeMarco et al. investigated a combinatorial approach of delivering innate immune agonists and RAS pathway-targeted therapies to remodel the tumour microenvironment and improve PDAC drug response.

Abstract Image

查看原文本刊更多论文

四管齐下打击 PDAC

Chibaya、DeMarco等人研究了一种提供先天性免疫激动剂和RAS通路靶向疗法的组合方法，以重塑肿瘤微环境并改善PDAC的药物反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.